NCT05564481

Brief Summary

Consistent use of continuous glucose monitors (CGM) has the potential to improve glycemic control and related type 1 diabetes (T1D) health outcomes, however young adolescents with T1D are the least likely age group to begin and sustain use of CGM. The proposed study will conduct a feasibility trial of a behavioral intervention designed to optimize use of CGM in adolescents specifically targeting underrepresented populations in diabetes technology research.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
6mo left

Started Jan 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress91%
Jan 2022Dec 2026

Study Start

First participant enrolled

January 1, 2022

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

August 26, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 3, 2022

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
1.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

July 3, 2025

Status Verified

July 1, 2025

Enrollment Period

3 years

First QC Date

August 26, 2022

Last Update Submit

July 1, 2025

Conditions

Outcome Measures

Primary Outcomes (8)

  • Glycemic control

    hemoglobin A1c (HbA1c)

    Baseline

  • Glycemic control

    hemoglobin A1c (HbA1c)

    3 months post randomization

  • Glycemic control

    hemoglobin A1c (HbA1c)

    6 months post randomization

  • Glycemic control

    hemoglobin A1c (HbA1c)

    12 months post randomization

  • glycemic variability

    Using 14-30 days of CGM data

    Baseline

  • glycemic variability

    Using 14-30 days of CGM data

    3 months post randomization

  • glycemic variability

    Using 14-30 days of CGM data

    6 months post randomization

  • glycemic variability

    Using 14-30 days of CGM data

    12 months post randomization

Secondary Outcomes (20)

  • Family Conflict

    Baseline

  • Family Conflict

    3 months post randomization

  • Family Conflict

    6 months post randomization

  • Family Conflict

    12 months post randomization

  • Diabetes Distress

    Baseline

  • +15 more secondary outcomes

Study Arms (2)

Immediate intervention

EXPERIMENTAL

Participants randomized to the immediate intervention group will participate in 3 video-conferencing sessions with a Certified Diabetes Care and Education Specialist (CDCES) interventionist and connect with a peer parent consultant immediately post randomization (expected intervention duration: 3 months).

Behavioral: diabetes education and parent coaching support

Wait-list/delayed intervention

ACTIVE COMPARATOR

Participants randomized to the delayed intervention group will receive no intervention for 6 months post-randomization; after the 6-month follow-up period, the delayed intervention group also will participate in 3 video conferencing sessions with a CDCES interventionist and connect with a peer parent consultant (expected intervention duration: 3 months).

Behavioral: diabetes education and parent coaching support

Interventions

Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.

Immediate interventionWait-list/delayed intervention

Eligibility Criteria

Age10 Years - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • years old
  • Type 1 diabetes
  • Type 1 diabetes diagnosis ≥ 6 months \\
  • Starting a continuous glucose monitor for the first time or restarting after ≥ 1 year

You may not qualify if:

  • Younger than 10, older than 15
  • Diagnosed less than 6 months
  • Already using CGM or has used within last year
  • Other major medical condition such as cancer, cystic fibrosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's National Research Institute

Washington D.C., District of Columbia, 20010, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Randi Streisand, PhD

    Children's National Hosptial

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
a research assistant blind to condition of participant will complete outcome assessments.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: wait-list control; all participants receive intervention- randomized to start immediately or 6 months after CGM start
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief of Psych/Behavioral Hlth

Study Record Dates

First Submitted

August 26, 2022

First Posted

October 3, 2022

Study Start

January 1, 2022

Primary Completion

January 1, 2025

Study Completion (Estimated)

December 1, 2026

Last Updated

July 3, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations